UBS Group
CLRBZ

UBS Group’s Cellectar Biosciences, Inc. Series A Warrants CLRBZ Stock Holding History

UBS Group’s Portfolio CLRBZ Stock Details CLRBZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,596
Closed -$1K – 10383
2021
Q1 		$1K Sell
1,596
-28,027
-95% -$7.63K ﹤0.01% 8902
2020
Q4 		$4K Buy
29,623
+26,405
+821% +$3.84K ﹤0.01% 7966
2020
Q3 		$0 Buy
3,218
+3,149
+4,564% +$416 ﹤0.01% 8684
2020
Q2 		$0 Sell
69
-1,221
-95% -$91 ﹤0.01% 8591
2020
Q1 		$0 Sell
1,290
-1,204
-48% -$118 ﹤0.01% 8661
2019
Q4 		$0 Sell
2,494
-6
-0.2% -$1 ﹤0.01% 8593
2019
Q3 		$0 Buy
+2,500
New +$140 ﹤0.01% 8426
2018
Q4 		– Sell
-14,674
Closed -$1K – 8464
2018
Q3 		$1K Buy
+14,674
New +$1.73K ﹤0.01% 7888
2017
Q3 		– Sell
-3,260
Closed -$2K – 8128
2017
Q2 		$2K Sell
3,260
-2,700
-45% -$1.7K ﹤0.01% 7425
2017
Q1 		$5K Buy
5,960
+5,780
+3,211% +$3.7K ﹤0.01% 7017
2016
Q4 		$0 Buy
+180
New +$100 ﹤0.01% 8163

UBS Group's CLRBZ Position: Q2 2021 in Review

UBS Group sold out of Cellectar Biosciences, Inc. Series A Warrants (CLRBZ) in Q2 2021, closing a stake of 1,596 shares — an estimated $1K sold.

UBS Group first reported a position in CLRBZ in Q4 2016 and held it in 11 quarters. The position peaked at $5K in Q1 2017. 0 funds tracked by Wall St. Rank hold CLRBZ as of Q2 2021.

  • UBS Group reported no remaining Cellectar Biosciences, Inc. Series A Warrants position as of Q2 2021 after selling out during the quarter.
  • UBS Group sold 1,596 Cellectar Biosciences, Inc. Series A Warrants shares in Q2 2021, an estimated $1K.
  • UBS Group first reported a position in Cellectar Biosciences, Inc. Series A Warrants in Q4 2016 and held it in 11 quarters.
  • UBS Group's Cellectar Biosciences, Inc. Series A Warrants position peaked at $5K in Q1 2017.
  • 0 funds tracked by Wall St. Rank held Cellectar Biosciences, Inc. Series A Warrants as of Q2 2021.

Based on UBS Group's 13F filing for Q2 2021, filed 13 Aug 2021.